本帖最后由 老马 于 2012-1-13 21:20 编辑 * S5 r* G0 ^) @3 e1 h
# f6 L Z; b) Z# _8 e, S; U
爱必妥和阿瓦斯丁的比较7 H) k5 ?* s8 I& P0 V
' t7 O) e8 ]1 c2 q6 C$ |
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/) T; E& ]3 U) w0 _; m
6 i/ }5 ~: L; E9 \6 g
0 O% {6 [# ?- \2 D% P) W
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/" V# I* m5 ~! \* G" L
==================================================7 T9 r2 C( g- j! @+ B7 C
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# v$ U( p7 L# v ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
3 w0 P2 x$ ^0 q* u6 nResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 }. y7 m+ E f+ o1 g
|